To Evaluate the Efficacy and Safety of Co-administrated HODO-2224-1 and HODO-2224-2 in Patients With Essential Hypertension and Primary Hypercholesterolemia
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hyundai Pharm
This trial is a phase 3 study to evaluate the efficacy and safety of Co-administrated HODO-2224-1 and HODO-2224-2 in Patients with Essential Hypertension and Primary Hypercholesterolemia.
This is multi-center, double-blind, Active-controlled, parallel-group, phase 3 study.
Age
19–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age ≥ 19
Patients with Essential Hypertension and Primary Hypercholesterolemia
You may not be if
Patients with differences between arms greater than 20 mmHg for mean sitSBP or 10 mmHg for mean sitDBP
Patients with mean sitSBP ≥ 180 mmHg or mean sitDBP ≥ 110 mmHg
Clareo Health | To Evaluate the Efficacy and Safety of Co-administrated HODO-2224-1 and HODO-2224-2 in Patients With Essential Hypertension and Primary Hypercholesterolemia
